# E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

> **NCT01692197** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** E7070
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01692197
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-01
- **Primary completion:** 2017-06-07
- **Final completion:** 2017-06-07
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2018-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01692197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01692197, "E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01692197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*